You are in: eMedicine Specialties > Physical Medicine and Rehabilitation > PLEXOPATHY Radiation-Induced Lumbosacral PlexopathyArticle Last Updated: Feb 6, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Rajesh R Yadav, MD, Assistant Professor, Section of Physical Medicine and Rehabilitation, MD Anderson Cancer Center, University of Texas at Houston Rajesh R Yadav is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation Editors: Robert J Kaplan, MD, Associate Professor, Department of Physical Medicine and Rehabilitation, University of Kansas School of Medicine and Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Michael T Andary, MD, MS, Residency Program Director, Associate Professor, Department of Physical Medicine and Rehabilitation, Michigan State University College of Osteopathic Medicine; Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center; Robert H Meier III, MD, Director, Amputee Services of America, Presbyterian St Luke's Hospital; Consulting Staff, North Valley Rehabilitation Hospital, Kindred Hospital, North Suburban Hospital Author and Editor Disclosure Synonyms and related keywords: radiation-induced lumbosacral plexopathy, lumbosacral plexus, radiation therapy, radiation plexopathy, chemotherapy, motor deficits, limb weakness, deep tendon reflex, DTR INTRODUCTIONBackgroundRadiation is used in the treatment of various neoplasms. When directed toward management of abdominal and pelvic malignancies, such treatment can result in lumbosacral plexopathy. Anatomically, lumbosacral plexus consists of lumbar (L1-L4) and sacral (L5-S5) portions, which are connected by the lumbosacral trunk (L4-L5). The L1-L4 nerve roots transverse through psoas muscle and then coalesce into lumbar plexus, which then divides into anterior and posterior divisions. The first 3 nerves (iliohypogastric, ilioinguinal, and femoral) of the 7 major branches of lumbar plexus provide motor and sensory innervation to the abdominal wall. The next 3 nerves (lateral femoral cutaneous, femoral, and obturator) innervate the anteromedial thigh. The femoral nerve terminates in the saphenous nerve providing sensation along the medial aspect of the leg. The sacral plexus also divides into anterior and posterior divisions, which further divide into various peripheral nerves providing sensory motor innervation to posterior hip girdle, thigh, and anterior and posterior leg. The 5 main nerves are superior gluteal, inferior gluteal, posterior femoral cutaneous, sciatic, and pudendal. The sciatic nerve divides into the common peroneal and tibial nerves in the thigh. PathophysiologyThe effects of radiation are correlated to the dose, technique, and concomitant use of chemotherapy. Also, risk particularly increases with intracavitary radiation. The mechanism may be related to a combination of localized ischemia and subsequent soft tissue fibrosis due to microvascular insufficiency. With doses above 1000 cGy, pathologic changes can be seen in Schwann cells, endoneurial fibroblasts, vascular cells, and perineural cells. Injury to anterior and posterior nerve roots in rodents has been shown with doses of 3500 Gy. Such plexopathy is noted particularly with uterine, cervical, ovarian, and testicular cancers, as well as lymphomas. FrequencyUnited StatesThe condition is rare (0.3-1.3% of patients treated with radiation). It was noted in 1.3% of patients after abdominal irradiation and in 0.32% of patients after pelvic irradiation. InternationalInternational incidence is unknown. Mortality/MorbidityGenerally, symptoms progress gradually and with variable rapidity. Clinical manifestations of lumbosacral plexopathy have appeared 3 months to 22 years after the completion of radiation therapy. Jaeckle et al found that 20% of patients developed moderate or even severe weakness over 6 months. Others were found to have mild weakness at 4-5 years following the onset of neurologic symptoms. RaceNo predilection toward any racial group is reported. SexThe male-to-female ratio is 1:1.2. AgeAge at the time of presentation ranges from 34-68 years, with median age of 47.5 years. CLINICALHistoryWith prior radiation treatment and initial symptoms, a recurrent tumor may need to be distinguished from postradiation plexopathy. The median symptom-free interval from treatment to the initial neurologic symptom is 5 years, with a range of 1-31 years.
Physical
CausesRadiation dosage, treatment technique, and concomitant use of chemotherapy are associated with development of radiation-induced lumbosacral plexopathy. DIFFERENTIALSDiabetic Lumbosacral Plexopathy Lumbar Degenerative Disk Disease Mononeuritis Multiplex Neoplastic Lumbosacral Plexopathy
|
| Drug Name | Amitriptyline (Elavil) |
|---|---|
| Description | Analgesic for certain chronic and neuropathic pain. Also has the most anticholinergic side effects of all drugs in this category. |
| Adult Dose | 10-100 mg PO qhs |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; use of MAOIs in past 14 d; history of seizures, cardiac arrhythmias, glaucoma, and urinary retention |
| Interactions | Phenobarbital may decrease effects; coadministration with CYP2D6 enzyme system inhibitors (eg, cimetidine, quinidine) may increase levels; inhibits hypotensive effects of guanethidine; may interact with thyroid medications, alcohol, CNS depressants, barbiturates, and disulfiram |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Caution in cardiac conduction disturbances and history of hyperthyroidism, and renal or hepatic impairment; avoid use in elderly patients |
These drugs stabilize neuronal membranes and reduce neuronal hyperexcitability. The analgesic effect may be due to such stabilization and control of hyperexcitability since aberrant electrical activity has been recorded with neuropathic pain.
| Drug Name | Gabapentin (Neurontin) |
|---|---|
| Description | Has anticonvulsant properties and antineuralgic effects; however, the exact mechanism of action is unknown. Structurally related to GABA but does not interact with GABA receptors. |
| Adult Dose | 300-3600 mg/d PO divided tid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids may reduce bioavailability of gabapentin significantly (administer at least 2 h following antacids); may increase norethindrone levels significantly |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in severe renal disease |
| Drug Name | Carbamazepine (Tegretol) |
|---|---|
| Description | Used typically for generalized tonic-clonic seizures and partial seizures, as well as trigeminal neuralgia. Plasma levels are between 4-12 mcg/mL for analgesic and antiseizure response. |
| Adult Dose | 100-200 mg PO bid initial dose; titrate up by 100-200 mg q3-7d; usual dosage for pain control is 400-800 mg/d; increase to tid/qid with larger dose; not to exceed 1200 mg; in rare instances, up to 1600 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; history of bone marrow depression; administration of MAOIs within last 14 d |
| Interactions | Serum levels may increase significantly within 30 days of danazol coadministration (avoid whenever possible); do not coadminister with MAOIs; cimetidine may increase toxicity, especially if taken in first 4 wk of therapy; carbamazepine may decrease primidone and phenobarbital levels (their coadministration may increase carbamazepine levels) |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Serious reactions include leukopenia and agranulocytosis; risk is 5-8 times higher than in control population; overall risk per 1,000,000 population per year is 2 patients for aplastic anemia and 6 patients for agranulocytosis; prior to treatment, obtain CBC counts and differentials, along with LFTs; repeat blood count in 2-3 wk and then monthly for 3 mo; if no evidence of bone marrow suppression, then biannual counts should follow; WBC counts below 4000 is contraindication to treatment; discontinue if WBC falls <3000 after treatment, significant thrombocytopenia, abnormality in other blood elements, or significant abnormality in LFTs; other rare drug adverse effects include cardiovascular effects, such as congestive heart failure, arrhythmias, and orthostatic hypotension; hepatotoxicity; inappropriate secretion of antidiuretic hormone (IASDH); severe dermatologic reactions, including Stevens-Johnson syndrome (extremely rare); caution with other TCAs |
| Drug Name | Valproic acid (Depakene) |
|---|---|
| Description | Generally indicated for absence seizures and generalized tonic-clonic seizures. Some relief may be noted with neuropathic pain, especially lancinating type. |
| Adult Dose | 15 mg/kg/d PO initial dose in 2 or more divided doses; titrate by 5-10 mg/kg/d until pain relief is achieved or adverse effects occur; pain relief at levels less than required for antiepileptic activity (50-150 mcg/mL) |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; hepatic disease/dysfunction |
| Interactions | Coadministration with cimetidine, salicylates, felbamate, and erythromycin may increase toxicity; rifampin may reduce valproate levels significantly; in pediatric patients, protein binding and metabolism of valproate decrease when taken concomitantly with salicylates; coadministration with carbamazepine may result in variable changes of carbamazepine concentrations with possible loss of seizure control; valproate may increase diazepam and ethosuximide toxicity (monitor closely); valproate may increase phenobarbital and phenytoin levels while either one may decrease valproate levels; valproate may displace warfarin from protein binding sites (monitor coagulation tests); may increase zidovudine levels in HIV seropositive patients |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Idiosyncratic reactions include hepatotoxicity (fatalities have been reported), dermatitis, alopecia, encephalopathy, and rare hyperammonemia syndrome; obtain baseline LFTs followed at frequent intervals for first 6 months; monitor serum ammonia, since it can be elevated without corresponding elevation in LFTs |
Glucocorticoids have anti-inflammatory, hormonal, and metabolic effects. Inflammation is suppressed with blockage of phospholipase A2, which inhibits formation of arachidonic acid and, thus, the prostaglandins. The analgesic effect may be due to the anti-inflammatory activity, with decrease in edema.
| Drug Name | Dexamethasone (Decadron, AK-Dex) |
|---|---|
| Description | For various allergic and inflammatory diseases. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reducing capillary permeability. |
| Adult Dose | 4-16 mg/d PO |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; systemic infections, especially fungal |
| Interactions | Decreased blood levels with phenytoin, phenobarbital, ephedrine, and rifampin; watch for development of hypokalemia with administration of potassium-depleting diuretics |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in DM, hypertension, renal impairment, osteoporosis, peptic ulcer disease, ocular herpes simplex, cirrhosis, hypothyroidism, and psychotic tendencies; concurrent use of NSAIDs not recommended due to GI toxicity; adverse effects can include hyperglycemia, hypertension, fluid retention, myopathy, osteoporosis, nausea, cataracts, glaucoma, peptic ulcers, convulsions, behavioral disturbances, increased susceptibility to infections, thromboembolism, change in leukocyte/lymphocyte count, malaise, impaired wound healing, increased appetite, and dermatologic effects |
These drugs are generally used for short-term acute pain, moderate to severe in nature, as well as in chronic pain (eg, cancer). They provide analgesia without antipyretic or anti-inflammatory action. Mechanism of action is inhibition of nociceptive impulses at the dorsal horn of the spinal cord and at supraspinal sites due to interaction with opiate receptors. Structural derivatives of GABA are also used in the management of neuropathic pain.
| Drug Name | Pregabalin (Lyrica) |
|---|---|
| Description | Structural derivative of GABA. Mechanism of action unknown. Binds with high affinity to alpha2-delta site (a calcium channel subunit). In vitro, reduces calcium-dependent release of several neurotransmitters, possibly by modulating calcium channel function. FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as adjunctive therapy in partial-onset seizures. |
| Adult Dose | 50 mg PO tid initially; if needed, may increase to 100 mg tid within 1 wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | May cause additive effects on cognitive and gross motor functioning when coadministered with drugs that cause dizziness or somnolence |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Discontinue gradually (over a minimum of 1 wk) to minimize increased seizure frequency in patients with seizure disorders; may cause insomnia, nausea, headache, or diarrhea with abrupt withdrawal; common adverse effects include dizziness, somnolence, blurred vision, weight gain, and peripheral edema; may elevate creatinine kinase level, decrease platelet count, and increase PR interval; doses >300 mg/d associated with higher rate of adverse effects and treatment discontinuation; decrease dose with renal impairment (ie, CrCl <60 mL/min) |
| Drug Name | Methadone (Dolophine) |
|---|---|
| Description | Used in the management of severe pain. Inhibits ascending pain pathways, diminishing the perception of and response to pain. |
| Adult Dose | 2.5-10 mg PO/IM/SC q3-8h prn; increase to a maintenance dose of 5-20 mg q6-8h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; bronchial asthma or increased intracranial pressure |
| Interactions | Phenytoin, rifampin, and pentazocine may decrease blood levels of methadone; phenothiazines, tricyclic antidepressants, MAOIs, and CNS depressants may increase the toxicity of methadone |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in severe liver disease; due to its relatively long half-life, titrate dose slowly |
| Drug Name | Morphine sulfate (Duramorph, MS Contin, Astramorph) |
|---|---|
| Description | Available in immediate (3-4 h duration) and extended release preparation (12 h). Switch over to long-acting preparations (MS Contin) once pain is controlled with short-acting preparation (MS IR). Morphine can produce drug dependence and has potential for being abused. Tolerance may develop with repeated exposure. Abrupt cessation or sudden reduction in dose with prolonged use may result in withdrawal symptoms. Physical dependence is not of paramount importance in terminally ill patients. |
| Adult Dose | 30 mg PO q3-4h initial dose in opiate-naive patients (no exposure to opiates) or with limited opiate exposure; may be titrated upward by 50% if pain control is inadequate after first 24 h; balance between analgesia and adverse effects |
| Pediatric Dose | 0.3 mg/kg PO q3-4h initial dose |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway where establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects of opiate agonists; TCAs, MAOIs, and other CNS depressants may potentiate adverse effects of morphine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Elderly patients; hepatic or renal dysfunction; respiratory disease, both obstructive and restrictive (eg, COPD, asthma, kyphoscoliosis); patients with severe obesity or cor pulmonale; head injury and increased intracranial pressure; history of drug abuse; circulatory shock; adverse effect profile includes nausea/vomiting, constipation, sedation, respiratory depression (which occurs more so with opiate-naive patients and with significant pulmonary disease), cardiovascular abnormalities (eg, bradycardia, hypotension), and urinary retention |
Radiation-Induced Lumbosacral Plexopathy excerpt
Article Last Updated: Feb 6, 2007